arrow
K

Karin Tarte

etablissement français du sang
H指数:62
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

二线阿西美单抗 ciloleucel 在不适合移植的大B细胞淋巴瘤中的最终分析

2026-09-230
OAAI
Aiolos and Eos drive distinct human TH17 functional states

Aiolos and Eos驱动不同的人类TH17功能状态

2026-04-010
OAAI
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL

患者来源的淋巴瘤球体揭示了Glofitamab耐药性的预测标志物在复发/难治性B-NHL中

Blood
IF23.1
2026-03-020
PRE
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells

髓系景观分析鉴定出与血内皮细胞共定位的DLBCL特异性抑制性巨噬细胞

2025-10-100
OAAI
Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases

定义间充质基质细胞治疗自身免疫性疾病临床试验同行评审报告的最小标准

2025-07-120
OAAI
Lymphoma B cells remodel bone marrow stromal cells into extracellular matrix–producing cancer-associated fibroblasts

淋巴瘤B细胞将骨髓基质细胞重塑为产生细胞外基质的肿瘤相关成纤维细胞

2025-05-050
OA
Blood immunophenotyping of multiple sclerosis patients at diagnosis identifies a classical monocyte subset associated to disease evolution

诊断时多发性硬化症患者的血液免疫表型鉴定出与疾病演变相关的经典单核细胞亚群

2025-01-080
OAAI
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial( vol 29 , pg 2593 , 2023)

Axicabtagene ciloleucel作为不适合自体干细胞移植的大b细胞淋巴瘤的二线治疗: 一项2期试验 (第29卷,2593页,2023页)

2024-05-140
OAAI
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

自身免疫性疾病的创新细胞疗法: EBMT实践协调和指导委员会的专家立场声明和临床实践建议

2024-03-0111
OAAI
NGFR regulates stromal cell activation in germinal centers

NGFR调控生发中心基质细胞活化

2024-02-011
OA
KDM6B drives epigenetic reprogramming associated with lymphoid stromal cell early commitment and immune properties

KDM6B驱动与淋巴样基质细胞早期承诺和免疫特性相关的表观遗传重编程

2023-12-011
OAAI
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial (Sept, 10.1038/s41591-023-02572-5, 2023)

Axicabtagene ciloleucel作为不适合自体干细胞移植的大b细胞淋巴瘤的二线治疗: 一项2期试验 (2023,10.1038/s41591-023-02572-5,9月)

2023-10-090
OAAI